2023-04-06 06:47:17 ET
- ImmunoGen ( NASDAQ: IMGN ) signed a term loan financing facility for up to $175M with entities managed by Pharmakon Advisors.
- The company said the funds will strengthen its balance sheet and provide additional capital to support growth.
- Under the agreement, the loan facility will be available in two tranches.
- The initial tranche of $75M will be drawn upon execution; the second of $50M will be available at the company's option after achieving positive top-line data from a confirmatory trial called MIRASOL and net sales threshold for cancer drug Elahere (mirvetuximab soravtansine-gynx). This tranche may be increased to $100M upon mutual agreement.
- "Our agreement with Pharmakon strengthens our financial position as we execute against our strategic priorities, including accelerating the launch of ELAHERE and investing in our pipeline of next-generation ADCs," said ImmunoGen's President and CEO Mark Enyedy.
For further details see:
ImmunoGen signs up for up to $175M loan